Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 3;70(9):1746–1757. doi: 10.1136/gutjnl-2020-320716

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Effects of combined cabozantinib/MLN0128 treatment on HCC cell proliferation and cell cycle. (A and C) Combined cabozantinib/MLN0128 treatment reduced cell proliferation in MHCC97-H and HLE cells. (B and D) The enhanced inhibitory effect of cabozantinib/MLN0128 combination on HCC in vitro growth is a synergistic action. (E and F) Representative western blot analysis phosphorylated MET, AKT/mTOR pathway, MAPK pathway and proliferation pathway in MHCC97-H and HLE cell lines. CC3, cleaved caspase 3; combo, combined cabozantinib/MLN0128 treatment; p, phosphorylated; t, total.